Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-α antagonists. - Institut Pasteur Access content directly
Journal Articles Travel Medicine and Infectious Disease Year : 2013

Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-α antagonists.

Abstract

Patients under immunosuppressive therapy with tumor necrosis factor alpha (TNF-α) antagonists are vulnerable to various opportunistic infections including leishmaniasis. We present a case series of 8 travellers developing cutaneous leishmaniasis whilst on TNF-α antagonist treatment and review the literature on aspects of cutaneous leishmaniasis developing in patients treated with TNF-α antagonists. We make interim recommendations regarding the drug therapy used to maintain remission in travellers with rheumatoid disease travelling to leishmania prone areas. Despite having a medical condition requiring continued rheumatological review the interval to diagnosis appears not to be reduced compared to that described in non-rheumatoid patients. Rheumatologists and family doctors should be aware of the need for post-travel surveillance for leishmaniasis in rheumatoid patients on TNF-alpha antagonist treatment.

Dates and versions

pasteur-00939151 , version 1 (30-01-2014)

Identifiers

Cite

Andreas L C Neumayr, Gloria Morizot, Leo G Visser, Diana N J Lockwood, Bernhard R Beck, et al.. Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-α antagonists.. Travel Medicine and Infectious Disease, 2013, 11 (6), pp.412-20. ⟨10.1016/j.tmaid.2013.05.003⟩. ⟨pasteur-00939151⟩
87 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More